Business Wire

MA-ADAGIO-THERAPEUTICS

29.7.2021 12:32:08 CEST | Business Wire | Press release

Share
Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Directors

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced the expansion of the company’s board of directors with key appointments, including:

  • Tom Heyman, former president of the Johnson & Johnson Development Corporation (JJDC)
  • Anand Shah, M.D., former deputy commissioner for medical and scientific affairs at the U.S. Food and Drug Administration (FDA)
  • Michael Wyzga, president of MSW Consulting, Inc.

“I am thrilled to welcome Tom, Anand and Mike to our board of directors, bringing unmatched expertise from their respective industry roles, and who join at a critical time as we prepare for potential commercialization of ADG20 to combat COVID-19, including rapidly emerging variants,” said Rene Russo, Adagio co-founder and chair of the board of directors. “Spanning his 37-year career with Johnson & Johnson, Tom held a diverse range of leadership roles across R&D, business development, corporate strategy and equity investments. As the deputy commissioner at the FDA until January 2021, Anand led consensus medical and scientific policy development and, during the COVID-19 pandemic, worked across the federal government and with the private sector to advance the development of vaccines and treatments.”

Jane Henderson, Adagio’s chief financial officer added, “Financial strength and discipline are of the utmost importance to our success as we advance several clinical trials with ADG20. We are thrilled to welcome Mike to our board, who brings years of experience leading exceptional financial operations at both public and private companies within the pharmaceutical industry. We look forward to partnering with him, as well as Tom and Anand, to benefit from their invaluable insights into clinical development, financial best practices, regulatory strategy, policy engagement and commercial execution, so that we may address this ongoing global pandemic today.”

Tom Heyman has a long-standing track record in the biopharmaceutical industry, with particular experience in business development and venture capital. He most recently served as president of JJDC, the venture capital group within Johnson & Johnson, where he managed approximately $1.5 billion of capital and oversaw investments in over 120 companies. Prior to his role at JJDC, Mr. Heyman spent 23 years leading business development for Johnson & Johnson’s pharmaceutical group, Janssen, where he was involved in hundreds of licensing and M&A transactions. Under his leadership, major licensing transactions were executed for products like Levaquin, Aciphex, Incivo, Olysio, Velcade, Invokana, Imbruvica, Xarelto and Darzalex, many of which have achieved sales of over $1 billion annually. Also, during his tenure, he led Janssen Belgium through a significant reorganization and implemented a new strategic plan for the site with a major emphasis on external innovation and value creation. Mr. Heyman graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.

Anand Shah, M.D., is a U.S. health policy leader who recently served as the deputy commissioner for medical and scientific affairs at the FDA. Dr. Shah led medical and scientific policy development for high priority programs including Advanced Manufacturing, the Coronavirus Treatment Acceleration Program, COVID-19 vaccine development, and decentralized clinical trials. Under his leadership, FDA initiated the Pandemic Recovery and Preparedness Plan (PREPP) to strengthen the response to the COVID-19 pandemic and resiliency for future public health emergencies. Dr. Shah represented FDA with top-level policy makers of the White House and Cabinet, Congress, and state and local governments. He previously served in senior leadership at the Centers for Medicare & Medicaid Services, both as senior medical advisor and chief medical officer of the Center for Medicare & Medicaid Innovation. Dr. Shah was chief resident during his radiation oncology residency at Columbia University. He concurrently earned his M.D. from the University of Pennsylvania and an M.P.H. in health care management and policy from the Harvard School of Public Health. Dr. Shah has an economics degree from Duke University.

Michael Wyzga is the president of MSW Consulting, Inc., a private company focused on strategic biotechnology consulting, a position he has held since November 2013. Prior to that, he served as president, chief executive officer and a member of the board of directors of Radius Health, Inc. From 1993 to 2011, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as executive vice president, finance and as chief financial officer. During his time with Genzyme, Mr. Wyzga played key roles in the successful development and commercialization of a number of important therapies, including Cerezyme for Gauche disease, Fabrazyme for Fabry’s disease, Renagel for use in the treatment of dialysis patients and Campath for chronic lymphocytic leukemia. Mr. Wyzga has served on a number of public company boards, including at Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc., X4 Pharmaceuticals, GenSight Biologics, LogicBio Therapeutics, Akebia Therapeutics, Inc., Idenix Pharmaceuticals, Inc., Prosensa Holding B.V. Mr. Wyzga received an MBA from Providence College and a B.S. from Suffolk University.

About Adagio Therapeutics

Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release

Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release

Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu

Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release

ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa

Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 08:06:00 CET | Press release

Crime Stoppers International asks the public to report illegal vapes and nicotine pouches as organised crime cashes in across Europe. Launched on the UN day against transnational organised crime: the criminals selling black market vapes and nicotine pouches also traffic fake medicine, illicit drugs and weapons. On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the

Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 08:00:00 CET | Press release

Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets. Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye